ABSCI
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
ABSCI
Industry:
Artificial Intelligence Biopharma Biotechnology Life Science
Founded:
2011-01-01
Address:
Vancouver, Washington, United States
Country:
United States
Website Url:
http://www.absci.com
Total Employee:
101+
Status:
Active
Contact:
360-949-1041
Email Addresses:
[email protected]
Total Funding:
237.86 M USD
Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Google Apps For Business GoDaddy DNS GoDaddy Google Web Toolkit
Similar Organizations
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Principia Biopharma
Principia Biopharma is dedicated to bringing oral therapies to patients with significant unmet medical needs in immunology & oncology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-14 | Totient | Totient acquired by Absci | N/A |
| 2021-01-12 | Denovium | Denovium acquired by Absci | N/A |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Venture Round - Absci
D1 Capital Partners
D1 Capital Partners investment in Venture Round - Absci
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Venture Round - Absci
aMoon Fund
aMoon Fund investment in Venture Round - Absci
Irving Investors
Irving Investors investment in Venture Round - Absci
Helicase Venture
Helicase Venture investment in Venture Round - Absci
ArrowMark Partners
ArrowMark Partners investment in Venture Round - Absci
Redmile Group
Redmile Group investment in Venture Round - Absci
Casdin Capital
Casdin Capital investment in Venture Round - Absci
Merck Global Health Innovation Fund
Merck Global Health Innovation Fund investment in Corporate Round - Absci
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-14 | Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires |
Official Site Inspections
http://www.absci.com Semrush global rank: 4.28 M Semrush visits lastest month: 2.71 K
- Host name: 104.26.6.50
- IP address: 104.26.6.50
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Absci"
About Us - Absci
What the world has been seeing over the last few months with the power of generative AI has been central to Absci's vision for years. Instead of looking for drugs like a needle in a haystack, we create them in silico using generative …See details»
Team - Absci
Dr. Taylor-Weiner leads Absci’s AI teams and technology, developing Absci’s first-in-class ability to design and validate de novo therapeutic antibodies with zero-shot generative AI. He brings …See details»
Absci - Crunchbase Company Profile & Funding
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ …See details»
Investor Relations | Absci Corp
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to …See details»
Absci - LinkedIn
Absci | 12,959 followers on LinkedIn. Creating Drugs at the Speed of Ai | Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better ...See details»
AbSci Company Profile - Office Locations, Competitors, Revenue
Aug 2, 2024 AbSci is a biotechnology company developing proteins for biotherapeutic medical treatments. The company offers the SoluPro platform and specializes in the production of …See details»
How Sean McClain founded Absci at just 22 - GeekWire
Jul 22, 2021 Absci ended the day with shares up 35% from its opening price on the company’s first day on the NASDAQ. The Vancouver, Wash.-based drug development platform company has a market capitalization ...See details»
Absci Corporation (ABSI) - Yahoo Finance Canada
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies …See details»
Thank you, E. coli: Vancouver’s Absci uses bacteria
Oct 31, 2021 Absci, which was also helping drug companies develop vaccines for COVID-19 in the early days of the pandemic, earned a back-to-back surge of investments for $65 million and $125 million. Earlier ...See details»
Absci Opens Door to New Biotechnology Campus
VANCOUVER, Wash., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to …See details»
Absci Becomes a Publicly Traded Company | Absci
Jul 22, 2021 Sean McClain celebrates today’s milestone moment as Absci becomes a publicly traded company. Ten years ago, with a vision to revolutionize the way protein-based drugs are …See details»
Absci Reports Third Quarter 2021 Financial and Operating Results
Sep 30, 2020 “At Absci, our team of Unlimiters is building technology to enable better, faster, smarter biologic drug and target discovery and cell line development,” said Sean McClain, …See details»
Absci Reports Business Updates and Third Quarter 2024
Nov 12, 2024 This amount includes the expected costs associated with advancing the IND-enabling studies for ABS-101 with a third-party contract research organization. Absci …See details»
Biotech startup AbSci raises $125M for ‘Protein Printing
Mar 23, 2021 A big year: AbSci raised a $65 million Series E round in October. In January it acquired Denovium, a small startup that uses deep learning to analyze the function and …See details»
Investor Relations | Absci Corp
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ …See details»
Absci Announces Research Collaboration with Merck
VANCOUVER, Wash., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to …See details»
Careers - Absci
Explore current careers at Absci and get ready to prove that impossible isn’t. Anyone can talk about changing the world. We’re actually doing it. Explore current careers at Absci and get …See details»
Absci Opens Door to New Biotechnology Campus - GlobeNewswire
Oct 20, 2021 Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug …See details»
Our Science | Absci
Explore groundbreaking transformative scientific content on our generative AI platform, shaping the future of medicine development. Learn more now!See details»